The expression level of BTBD10, an independent prognostic risk factor, provides a quantitative method for clinicians to predict the likelihood of progression-free survival at 1, 3, and 5 years for HCC patients (Figures 4A,B). Here, BTBD10 is linked to hepatocellular carcinoma.